Skip to the page

Data / Form D filings / Omnipulse Biosciences, Inc.

Omnipulse Biosciences, Inc.: Form D filing

Omnipulse Biosciences, Inc., a biotechnology company in Cambridge, MA, filed a Form D with the SEC in 2024. The latest, on January 2, 2024, reports $7 million sold of a $12.5 million offering to 2 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
238 Main Street, Cambridge, MA, 02142
Phone
(978) 999-2040
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2022
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
1976713

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Jan 2, 2024New notice$12,500,000$6,999,999$5,500,0012Dec 15, 2023sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Ana JacklenecDirector, Promoter
David ZhuDirector
Robert FarraExecutive Officer, Director
Joseph DeSimonePromoter
Felicia HsuDirector
Robert LangerDirector, Promoter

Other biotechnology companies in Massachusetts that filed recently

Every Form D from the week of Jan 1, 2024 · All recent filings in Massachusetts · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Omnipulse Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.